- The Street Sheet
- Posts
- 👁️ Small Name, Big Future
👁️ Small Name, Big Future
Plus, a bold blend is being retired, but not everyone will miss it.
Happy Wednesday afternoon to everyone on The Street. Here's a snapshot of where markets ended the trading session, plus tomorrow's trade idea delivered to you today.
🟥 | US stocks fell as investors reacted to mixed results on the earnings front. The S&P 500 fell 0.3%, the Dow slipped 0.2%, and the Nasdaq lost 0.6% despite it hitting a record high earlier.
📈 | One Notable Gainer: Reddit shares surged 42% after posting a strong Q3, with earnings of $0.16 per share and $348.4M in revenue, both exceeding analyst expectations.
📉 | One Notable Decliner: Super Micro Computer shares fell 32.7% after auditor EY resigned, citing concerns over board independence and accounting practices in a regulatory filing.
👁️ | Tomorrow's Trade: Small Name, Big Future. Scroll down for more.
Plus, today’s sponsor outlines why they think this is a winning momentum trade this week…
GO DEEPER
Get Access to Private Investments: Looking for access to private investment opportunities including direct real estate investments and venture capital investments? Click here to fill out this form.
Grow Your Business: Do you work in the financial services industry? Do you need help with email and content marketing to generate new leads, retain clients, and grow your bottom line? We work with companies ranging from J.P. Morgan to independent financial advisors to help them do exactly that. Click here to fill out this form and schedule a call.
SPONSORED & WRITTEN BY WINNING TRADES
3 Reasons You'll Be Glad You Added Therma Bright To Your Watchlist.
S&P 500 Heatmap. Credit: Finviz
All Stock Heatmap. Credit: Finviz
Global ADR snapshot. Credit: Finviz
MARKET MOVERS
GRMN (+23.2%) Garmin Smashes Third-Quarter Views, Guides Higher. Stock Breaks Out. (IBD)
LLY (-6.3%) Eli Lilly plans to begin advertising weight-loss drug Zepbound (YF)
WING (-21.4%) Wingstop Shares Gap Down - Here's What Happened (MarketBeat)
SHAK (+7.8%) Shake Shack Reports Q3 In Line With Expectations, Stock Soars (StockStory)
CZR (-8.2%) Caesars Entertainment Shares Gap Down Following Weak Earnings (MarketBeat)
OVERHEARD ON THE STREET
CNBC: Novo Nordisk's Ozempic and Wegovy are now fully available in the U.S., signaling supply improvements as demand surges.
Axios: The E. coli outbreak linked to Quarter Pounders has hurt McDonald's sales and foot traffic, pressuring the chain to rebuild customer trust.
CNBC: Starbucks will remove Oleato olive oil drinks from U.S. menus in November, aligning with new CEO Niccol's strategy to simplify offerings.
Fast Company: DOT and Delta announced plans for wheelchair-adaptive seats, allowing passengers to remain in their wheelchairs for a more comfortable flight.
Reuters: Apple unveiled new MacBook Pro models with M4 Pro and M4 Max processors, starting at $1,599 for the 14-inch and $2,499 for the 16-inch.
TOMORROW’S TRADE IDEA, TODAY
Small Name, Big Future
40% Upside
According to Jefferies analyst Young Li, ocular implant manufacturer RxSight (RXST) could see an over 40% jump in its share price. The analyst initiated coverage at a buy rating and a $72 price target.
Li is bullish on the company’s unique post-surgery adjustable intraocular lens technology for cataract patients, which he believes helps set it apart from its competition and will lead to an increase in US market share.
Changing the Game
However, that isn’t the only technology serving as a potential tailwind: its Light Adjustable Lens (LAL) also has the potential to increase its market share from 10% to 50%. Li believes that this growth will come by means of strong clinical results, rising adoption rates and increased usage.
If Li is correct, RXST will be able to establish itself at the forefront of advanced intraocular lens solutions.
It Could Go Even Higher
Jefferies believes that its LAL market could be worth some $6 billion by 2027, and that is its conservative estimate. At present, around half of intraocular lens patients are eligible for LALs. Due to that figure, Jefferies is projecting 45% growth by 2025.
The shares are up around 25% YTD, and Li is projecting another 43% upside, but Jefferies believes that it has the potential to climb to $90 per share, $18 above Li’s price target.
Are you bullish or bearish on RxSight (RXST) over the next 12 months? |
TOGETHER WITH EXPRESS
Each Express Employment Professionals location is locally owned and operated, offering you connections in your community to your next job. With Express, you’ll have a local recruiter you can meet with and explore job opportunities, whether you are looking for a new career path or your next job. Express helps job seekers in a variety of industries, including customer service, IT, logistics, manufacturing – they can help you find just about any type of job. With more than 860 locations, you are sure to have an office nearby.
ON OUR RADAR
CNBC: Despite cooling inflation, many Americans still live paycheck to paycheck, struggling with high prices that hinder middle-class status.
WSJ: U.S. crude oil inventories fell by 515,000 barrels to 425.5 million, about 4% below the five-year average, as imports declined.
Reuters: U.S. consumer spending surged in Q3, boosting economic growth and defying recession forecasts ahead of the Nov. 5 election.
WSJ: Home builders’ stocks have soared despite high interest rates, but as mortgage costs decline, competition for buyers may increase.
Axios: Harris' food price plan is stalled in legal limbo as FTC efforts to block Kroger's purchase of Albertsons face unexpected delays.
TUESDAY’S POLL RESULTS
🟩🟩🟩🟩🟩🟩 Norwegian Cruise Line (NCLH)
🟨🟨🟨🟨⬜️⬜️ MetLife (MET)
This message is a paid advertisement for Therma Bright Inc. (TSXV: THRM), (OTCQB: TBRIF), (FRA: JNX). The Street Sheet (SS) receives a flat fee totaling up to $2,422.00. Other than the compensation received for this advertisement sent to subscribers, The Street Sheet and its principals are not affiliated with Therma Bright Inc. The Street Sheet and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SS chooses to do trades at their sole discretion and risk. SS is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SS receives some sort of compensation is clearly and prominently identified herein as "ad", "Sponsored", or “Together With”. Although we have sent you these advertisements, SS does not specifically endorse any third-party product nor is it responsible for the content, the accuracy, or the completeness of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is in the advertisement. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. This communication from The Street Sheet is for informational purposes only. It is not intended to serve as a recommendation to buy, sell, or hold any security and is not an offer or sale of a security. Information contained within should not be perceived as a research report and is not intended to serve as the basis for any investment decision. Any third-party views reflected herein do not reflect the opinion of The Street Sheet. All investments involve risk and the past performance of a security does not guarantee future results or returns. There is always the potential for financial loss when investing in securities or other financial products. The information contained in this newsletter is subject to change without notice, and we do not undertake any obligation to update it. Readers are encouraged to conduct their own research and due diligence and seek advice from licensed professionals regarding their specific financial needs and circumstances. By reading this newsletter, you agree to hold us harmless from any and all losses, liabilities, costs, or expenses arising from your use or reliance on the information provided. There is no warranty as to the accuracy or completeness of the factual matters included in any advertisement or sponsored content in the newsletter. You have not performed any research on any entity, or its business, that advertises or submits any sponsored content. The Street Sheet is reader-supported. When you buy through links on our site, we may earn an commission.
Reply